Fulcrum Therapeutics director granted 32,000 stock options

Fulcrum Therapeutics director Katina Dorton received a new stock option award covering 32,000 shares of Common Stock.

Rhea-AI Filing Summary

Fulcrum Therapeutics director Katina Dorton received a new stock option award covering 32,000 shares of Common Stock. The option carries an exercise price of $3.66 per share and expires on June 29, 2036. It was granted at no upfront cost and is scheduled to vest in full on the first anniversary of the June 30, 2026 grant date or earlier, immediately before the first annual stockholder meeting after the grant date, subject to continued service. Following this grant, Dorton holds 32,000 stock options directly from this award.

Insider Trade Summary

Grant/Award: 32,000 shares

Grant/Award 1 txn

Insider Dorton Katina

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	32,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 32,000 contracts (Direct)

Footnotes (1)

1. F1. This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

Key Figures

Stock options granted: 32,000 options Exercise price: $3.66 per share Expiration date: June 29, 2036 +2 more

5 metrics

Stock options granted 32,000 options Grant on June 30, 2026 to director Katina Dorton

Exercise price $3.66 per share Exercise price for 32,000 option shares

Expiration date June 29, 2036 Option expiration for 32,000-share grant

Shares underlying options 32,000 shares Underlying Fulcrum Therapeutics Common Stock

Total derivative holdings after grant 32,000 options Total stock options reported following this transaction

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, vesting, Common Stock

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

vesting financial

"is scheduled to vest with respect to all shares on the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Fulcrum Therapeutics (FULC) director Katina Dorton receive in this Form 4?

Katina Dorton received a stock option grant for 32,000 shares of Fulcrum Therapeutics Common Stock. The option was awarded at no upfront cost and represents a compensation-related acquisition rather than an open-market share purchase or sale.

What is the exercise price of Katina Dorton’s new Fulcrum Therapeutics stock options?

The stock options have an exercise price of $3.66 per share. This means Dorton can buy up to 32,000 Fulcrum Therapeutics Common Stock shares at $3.66 each once the options are vested and exercisable, subject to the stated terms.

When do Katina Dorton’s Fulcrum Therapeutics stock options vest?

The options are scheduled to vest with respect to all 32,000 shares on the first anniversary of the June 30, 2026 grant date. They may alternatively vest earlier, immediately before the first annual meeting of stockholders after the grant date, subject to continued service.

When do the Fulcrum Therapeutics stock options granted to Katina Dorton expire?

The stock options granted to Katina Dorton expire on June 29, 2036. After this expiration date, any unexercised portion of the 32,000-share option will no longer be exercisable, so the exercise opportunity is limited to the period before that date.

How many Fulcrum Therapeutics derivative securities does Katina Dorton hold after this transaction?

Following this transaction, Katina Dorton holds 32,000 stock options as reported. These options relate to 32,000 shares of Fulcrum Therapeutics Common Stock and are held directly, reflecting the full amount of the newly granted award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dorton Katina

(Last) (First) (Middle)

C/O FULCRUM THERAPEUTICS, INC.

26 LANDSDOWNE STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Fulcrum Therapeutics, Inc. [ FULC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.66	06/30/2026		A		32,000		(1)	06/29/2036	Common Stock	32,000	$0.00	32,000	D

Explanation of Responses:

1. This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

	/s/ Greg Tourangeau, as attorney-in-fact for Katina Dorton	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)